ABT · News · 20261102N

Cephea Product Pipeline Progress

ABBOTT LABORATORIES · 2026-11-02 · Importance 34 · Surprise 42

Abbott initiated a pivotal clinical trial of its investigational Cephea mitral valve system, designed to replace diseased mitral valves and restore normal blood flow. Unlike Abbott’s Tendyne system, Cephea is delivered through a leg vein rather than through a chest incision. The trial plans to enroll up to 585 patients across the U.S., Canada, and Europe. Abbott believes the device could significantly expand the mitral valve market.

Key facts

• Abbott initiated a pivotal clinical trial for its investigational Cephea mitral valve system. source
• Abbott aims to enroll up to 585 patients in the Cephea trial across the U.S., Canada, and Europe. source
• Abbott’s Cephea system is delivered via a leg vein, unlike its Tendyne system, which is delivered via a chest incision. source
• Abbott acquired the Cephea device in 2019. source